- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07386223
Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA RCT) (HEAL-FHA)
A Digital Psychoeducational Self-help Program Versus Usual Care to Restore Ovulatory Menstrual Cycles in Women With Functional Hypothalamic Amenorrhea: a Randomized Controlled Trial (HEAL-FHA RCT)
The goal of this clinical trial is to learn whether a 10-week digital psychoeducational health and lifestyle program can help women with functional hypothalamic amenorrhea (FHA) recover ovulatory menstrual cycles and endocrine function.
The main questions the study aims to answer are:
Does the program increase the proportion of women who have at least one spontaneous ovulatory menstrual cycle within 12 months? Does it improve hormonal markers of recovery of the hypothalamic-pituitary-ovarian axis, such as LH, FSH, estradiol and T3? Does it improve psychological well-being, stress and eating-related symptoms?
Researchers will compare the program with usual care to see whether the structured program leads to faster or more frequent recovery of menstrual and endocrine function than the care women typically receive today.
Participants will:
Be randomly assigned to the 10-week digital self-help program, delivered via the Swedish healthcare platform 1177 with one module per week (intervention group), or to usual care with a consultation with a gynecologist (comparison group); the comparison group is offered the program after the study Complete questionnaires and a structured diagnostic interview Provide blood samples to measure hormone levels at 3, 6, 9 and 12 months Contact the clinic if menstrual bleeding occurs, so that a blood sample can confirm ovulation Have a gynecological examination with ultrasound after 12 months to assess ovarian activity and endometrial thickness
This study builds on an ongoing feasibility study (NCT07589868) and will help determine whether the program is effective and should be offered more widely to women with FHA.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
The study is a randomized, controlled trial with multicentre recruitment evaluating a 10-week digital psychoeducational health and lifestyle program with 12 months of follow-up in women with functional hypothalamic amenorrhea (FHA).
Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation and self-management skills. The program is compared with usual care to determine whether it leads to superior restoration of ovulatory menstrual cycles and endocrine function.
Study Aim To evaluate whether a 10-week digital psychoeducational program, compared with usual care, increases the proportion of women with FHA who recover spontaneous ovulatory menstrual cycles within 12 months.
Study Setting and Participants Seventy women aged 18-40 years with FHA (amenorrhea for ≥3 months and with a hypothalamic hormone profile: FSH <10 IU/L, LH <10 IU/L and estradiol <200 pmol/L after exclusion of other causes of amenorrhea) are recruited through several gynecological clinics, with central coordination at Karolinska University Hospital. Individuals who meet exclusion criteria receive appropriate clinical information, standard care or referral to relevant healthcare services.
Intervention and Comparator The intervention is a 10-week self-help program delivered via the Swedish healthcare platform 1177 (Stöd och behandling) with one module per week and no therapist support. The comparison group receives usual care, including a consultation with a gynecologist with standard information about FHA, and is offered the program after the 12-month follow-up.
Sample Size In the only previous randomized trial (Berga et al. 2003), ovarian activity recovered in 87.5% of women receiving individual cognitive behavioural therapy compared with 25% with observation. Because small trials tend to overestimate effects, and because the present intervention is a digital self-help program with a stricter primary outcome, a difference of 60% versus 25% is assumed. With 80% power and two-sided α = 0.05, 30 evaluable participants per arm are required. Allowing for 15% attrition, 35 participants per arm (70 in total) will be randomized.
Study Design and Assessments Two-arm, parallel-group superiority trial with 1:1 allocation. Randomization is performed centrally by Karolinska Trial Alliance, stratified by FHA severity at baseline (severe: estradiol <80 pmol/L and LH <2.4 IU/L), with randomly varying block sizes. At the screening visit, all individuals complete the DIAMOND screening questions and the complete eating disorder module, with further modules after a positive screening question. Validated questionnaires (including EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6) and blood sampling (LH, FSH, estradiol, T3 and other hormones) are performed at baseline and at 3, 6, 9 and 12 months, with gynecological follow-up by video or in person. A gynecological examination with transvaginal ultrasound is performed at 12 months.
Data and Sample Collection Questionnaire data are collected electronically via REDCap. Findings from the feasibility study (NCT07589868) and the qualitative interview study inform the final protocol. Participants contact the clinic if menstrual bleeding occurs, and serum progesterone is measured on cycle day 21, counting the first day of bleeding as day 1, to assess ovulation.
Outcome Measures The primary outcome is the proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above [threshold] nmol/L) within 12 months. Secondary outcomes include time to first ovulatory cycle, number of spontaneous cycles, sustained recovery (≥3 consecutive cycles), change in LH, FSH, estradiol and T3, ultrasound signs of ovarian activity, psychological symptoms and well-being, and adverse events.
Statistical Analysis The primary analysis follows the intention-to-treat principle and compares the proportion with at least one spontaneous ovulatory cycle between groups, with the risk difference and 95% confidence interval and logistic regression adjusted for the stratification factor. Missing primary outcome data are handled with multiple imputation, with complete-case and worst-case sensitivity analyses. Secondary menstrual outcomes are analyzed with time-to-event methods and longitudinal outcomes with methods for repeated measurements. A detailed statistical analysis plan will be finalized before database lock.
Ethical Considerations Informed consent is obtained from all participants. The project is approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01, with amendments 2025-07620-02 and 2026-06250-02). The overall risk to participants is considered low, and adverse events are monitored throughout the study period.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Hedvig Engberg, MD PhD
- Puhelinnumero: +46 08 123 795 02
- Sähköposti: hedvig.engberg@ki.se
Tutki yhteystietojen varmuuskopiointi
- Nimi: Anna Strandqvist, PhD
- Puhelinnumero: +46 08 123 779 69
- Sähköposti: anna.strandqvist@ki.se
Opiskelupaikat
-
-
-
Stockholm, Ruotsi
- Kvinnohälsan Karolinska Universitetssjukhuset
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion criteria:
- Women aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist
- amenorrhea for at least 3 months
- a history compatible with functional hypothalamic amenorrhea
- exclusion of other causes of amenorrhea
- able to read and understand Swedish
- access to an internet-enabled device and BankID
- written informed consent.
Exclusion criteria:
- Current anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion)
- severe psychiatric comorbidity requiring other or more intensive care, including psychosis
- insufficient Swedish proficiency
- other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Psychoeducational Intervention
Behavioral: HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months. |
HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months. |
|
Active Comparator: Treatment as Usual (TAU)
Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months; access to the program offered after 12 months. |
Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of participants with return of spontaneous menstrual bleeding within 12 months from baseline.
Aikaikkuna: Restoration of menstruation after 12 months of follow-up from baseline.
|
Proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above 13 nmol/L. [Time frame: 12 months]. |
Restoration of menstruation after 12 months of follow-up from baseline.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to spontaneous ovulatory cycles within 12 months from baseline.
Aikaikkuna: Baseline to 12 months
|
Time to first spontaneous ovulatory cycle; number of spontaneous cycles; sustained recovery (≥3 consecutive spontaneous cycles) |
Baseline to 12 months
|
|
Change in BMI within 12 months from baseline.
Aikaikkuna: 6 and 12 months from baseline
|
Weight and height will be combined to report BMI in kg/m^2 |
6 and 12 months from baseline
|
|
Change in serum luteinizing hormone (LH)
Aikaikkuna: Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum luteinizing hormone (LH). |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in serum follicle-stimulating hormone (FSH)
Aikaikkuna: Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum FSH (IU/L). |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in serum estradiol (E2)
Aikaikkuna: Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum estradiol (pmol/L), sensitive LC-MS/MS method. |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in serum triiodothyronine (T3)
Aikaikkuna: Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
Change from baseline in serum T3 ([nmol/L or pmol/L, if free T3 - check with the laboratory]). |
Baseline to 12 months (also assessed at 3, 6 and 9 months)
|
|
Change in eating disorder symptoms (EDE-Q)
Aikaikkuna: Baseline to 12 months
|
Change from baseline in Eating Disorder Examination Questionnaire 6.0 global score (range 0-6; higher scores indicate more symptoms). |
Baseline to 12 months
|
|
Change in perceived stress (PSS-14)
Aikaikkuna: Baseline to 12 months
|
Change from baseline in Perceived Stress Scale total score (range 0-56; higher scores indicate more stress). |
Baseline to 12 months
|
|
Change in anxiety symptoms (GAD-7)
Aikaikkuna: Baseline to 12 months
|
Change from baseline in GAD-7 total score (range 0-21; higher scores indicate more anxiety). |
Baseline to 12 months
|
|
Change in depressive symptoms (PHQ-9)
Aikaikkuna: Baseline to 12 months
|
Change from baseline in PHQ-9 total score (range 0-27; higher scores indicate more depressive symptoms). |
Baseline to 12 months
|
|
Change in well-being (WHO-5)
Aikaikkuna: Baseline to 12 months
|
Change from baseline in WHO-5 percentage score (range 0-100; higher scores indicate better well-being). |
Baseline to 12 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2023-05586-01
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
What data will be shared:
De-identified individual participant data collected during the trial, including:
Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments
Other documents to be shared:
Data dictionary describing all variables and coding used Study protocol and statistical analysis plan
IPD-jaon aikakehys
When data will become available and for how long:
Data will be available 6 months after publication of the primary trial results and will remain accessible for 5 years.
IPD-jaon käyttöoikeuskriteerit
By what access criteria:
Data will be available to qualified researchers for scientific purposes following submission of a research proposal and approval by the trial steering committee. Requests should be sent to the corresponding author or data custodian (contact information provided in the study publication).Data will be shared via a secure data repository
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .